SYRS
Syros Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.00
+0.00%Year over year
Reported trailing growth
- Revenue
- -90.5%
- EBITDA
- +6.2%
- EBIT
- +19.1%
- EPS
- -32.7%
- Free cash flow
- +18.7%
- Operating cash flow
- +18.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -13.0%
- EBITDA
- -79.5%
- EBIT
- +5.1%
- Net income
- -73.9%
- EPS
- +22.4%
- Free cash flow
- +11.5%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2024